• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    General Counsel Garcia Ruben A bought $13,056 worth of shares (40,000 units at $0.33), increasing direct ownership by 29% to 180,000 units (SEC Form 4)

    3/2/26 9:15:05 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FBLG alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    GARCIA RUBEN A

    (Last) (First) (Middle)
    C/O FIBROBIOLOGICS, INC.
    455 E. MEDICAL CENTER BLVD., SUITE 300

    (Street)
    HOUSTON, TX 77598

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    FibroBiologics, Inc. [ FBLG ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    General Counsel
    3. Date of Earliest Transaction (Month/Day/Year)
    02/27/2026
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 02/27/2026 P 40,000 A $0.3264(1) 180,000 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $0.3221 to $0.3268 on February 27, 2026. The reporting person will provide upon request to the SEC, the Issuer, or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
    /s/ Ruben A. Garcia 03/02/2026
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $FBLG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FBLG

    DatePrice TargetRatingAnalyst
    12/12/2024$12.00Buy
    Rodman & Renshaw
    10/30/2024$12.00Buy
    H.C. Wainwright
    9/24/2024$12.00Buy
    Maxim Group
    More analyst ratings

    $FBLG
    SEC Filings

    View All

    FibroBiologics Inc. filed SEC Form 8-K: Leadership Update

    8-K - FibroBiologics, Inc. (0001958777) (Filer)

    3/6/26 4:03:48 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by FibroBiologics Inc.

    10-K - FibroBiologics, Inc. (0001958777) (Filer)

    2/24/26 4:06:52 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroBiologics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - FibroBiologics, Inc. (0001958777) (Filer)

    2/23/26 4:18:54 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBLG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

    HOUSTON, March 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that onboarding of the clinical sites has been completed for its Phase 1/2 clinical trial evaluating the safety and efficacy of CYWC628 for the treatment of refractory diabetic foot ulcers (DFUs). The clinical trial is a prospective, multicenter, open label study designed to evaluate the safety, tolerability, and efficacy of FibroBiologics' investigational topica

    3/5/26 8:30:00 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them

    Issued on behalf of Avaí Bio, Inc.VANCOUVER, BC, March 3, 2026 /CNW/ -- USANewsGroup.com News Commentary -- The global cell therapy market is projected to surpass $8.2 billion in 2026, driven by a wave of clinical breakthroughs and manufacturing milestones reshaping regenerative medicine[1]. CAR T-cell therapy alone is valued at nearly $7 billion this year, expanding at an 18% compound annual growth rate as off-the-shelf platforms eliminate the logistical barriers that once limited patient access[2]. Among the companies advancing next-generation cell-based treatments are Avaí Bio (OTCQB:AVAI), FibroBiologics (NASDAQ:FBLG), Fate Therapeutics (NASDAQ:FATE), Mesoblast (NASDAQ:MESO), and Longeve

    3/3/26 10:02:00 AM ET
    $FATE
    $FBLG
    $LGVN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis

    HOUSTON, March 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the issuance of a new U.S. patent entitled "Fibroblast Cell Therapy for Treatment of Osteoporosis." The United States Patent and Trademark Office has issued U.S. Patent No. 12,544,407 B2, dated February 10, 2026, further strengthening FibroBiologics' intellectual property portfolio in regenerative medicine and bone-related disorders. The patent

    3/2/26 8:30:00 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBLG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Khoja Hamid bought $11,400 worth of shares (30,000 units at $0.38), increasing direct ownership by 96% to 61,250 units (SEC Form 4)

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    3/5/26 8:00:15 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER O'Heeron Pete bought $19,531 worth of shares (51,500 units at $0.38), increasing direct ownership by 0.87% to 5,958,147 units (SEC Form 4)

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    3/4/26 5:50:10 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Davis Jason bought $28,973 worth of shares (70,000 units at $0.41) (SEC Form 4)

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    3/3/26 8:00:20 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBLG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on FibroBiologics with a new price target

    Rodman & Renshaw initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00

    12/12/24 8:54:24 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on FibroBiologics with a new price target

    H.C. Wainwright initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00

    10/30/24 6:37:36 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on FibroBiologics with a new price target

    Maxim Group initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00

    9/24/24 7:59:12 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBLG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Khoja Hamid bought $11,400 worth of shares (30,000 units at $0.38), increasing direct ownership by 96% to 61,250 units (SEC Form 4)

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    3/5/26 8:00:15 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER O'Heeron Pete bought $19,531 worth of shares (51,500 units at $0.38), increasing direct ownership by 0.87% to 5,958,147 units (SEC Form 4)

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    3/4/26 5:50:10 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Davis Jason bought $28,973 worth of shares (70,000 units at $0.41) (SEC Form 4)

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    3/3/26 8:00:20 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBLG
    Leadership Updates

    Live Leadership Updates

    View All

    FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced second quarter 2025 financial results and provided a corporate update. Recent Highlights Successfully closed third $5 million tranche of a $25 million total financing, with proceeds used to advance research and development efforts and support the upcoming Phase 1/2 clinical trial in diabetic foot ulcers (DFUs).Strengthened leadership team with the appointment of

    7/31/25 4:30:00 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer

    HOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the appointment of Jason D. Davis, CPA, as Chief Financial Officer, effective immediately. Mr. Davis brings extensive experience in corporate finance, capital markets, and SEC reporting, with a proven track record of successfully leading companies through critical growth phases, including IPOs and capital raising initiatives. His appointment comes as FibroBiologic

    6/9/25 8:30:00 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroBiologics Set to Join Russell 2000® Index

    HOUSTON, June 13, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced today it is set to join the Russell 2000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them b

    6/13/24 9:31:00 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care